Andrew Davis
Corporate Officer/Principal chez IRONWOOD PHARMACEUTICALS, INC.
Fortune : 3 M $ au 31/03/2024
Profil
Andrew Davis is currently the Chairman at VectivBio Holding AG since 2023.
He is also the Director at UTILITY therapeutics Ltd.
since 2019 and the Chief Business Officer & Senior Vice President at Ironwood Pharmaceuticals, Inc. since 2021.
Previously, he served as the Director at BioMarck Pharmaceuticals Ltd.
from 2020 to 2022.
He was the Senior Vice President-Business Development at Bausch Health US LLC from 2014 to 2016.
He also held the position of Vice President-Corporate Development at Bausch Health Cos., Inc. He served as the Chief Business Development Officer at iNova Pharmaceuticals (Pty) Ltd.
(South Africa) from 2017 to 2021.
Additionally, he was the Head-Oncology Business Development at Merck & Co., Inc. in 2016.
Mr. Davis completed his undergraduate degree at Boston University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/03/2024 | 310 756 ( 0,20% ) | 3 M $ | 31/03/2024 |
Postes actifs de Andrew Davis
| Sociétés | Poste | Début |
|---|---|---|
| IRONWOOD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/05/2021 |
UTILITY therapeutics Ltd.
 UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Director/Board Member | 01/08/2019 |
Anciens postes connus de Andrew Davis
| Sociétés | Poste | Fin |
|---|---|---|
BioMarck Pharmaceuticals Ltd.
 BioMarck Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology BioMarck Pharmaceuticals Ltd. engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders. It develops its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. The company was founded by Indu Parikh, Allen F. Gant, Thomas H. Roberg and Kenneth Adl in 2002 and is headquartered in Durham, NC. | Director/Board Member | 01/10/2022 |
iNova Pharmaceuticals (Pty) Ltd. (South Africa)
 iNova Pharmaceuticals (Pty) Ltd. (South Africa) Pharmaceuticals: MajorHealth Technology Part of iNova Pharmaceuticals (Australia) Pty Ltd., iNova Pharmaceuticals (Pty) Ltd. is a South African company that develops and markets a range of healthcare products. The private company is based in Bedfordview, South Africa. The company's products include B-CAL-K2, a calcium and bone health supplement with clinically proven K2, and PregOmega Plus, a multivitamin and mineral supplement for pregnancy. The company is committed to promoting and manufacturing quality products that bring real benefits and comply with Good Manufacturing Practices (GMP). | Corporate Officer/Principal | 01/05/2021 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/09/2017 |
Bausch Health US LLC
 Bausch Health US LLC Pharmaceuticals: MajorHealth Technology Bausch Health US LLC engages in the development, manufacture and market of pharmaceutical products. It specializes in therapeutic areas of neurology, dermatology, and infectious diseases. The company was founded in 2001 and is headquartered in Raleigh, NC. | Corporate Officer/Principal | 01/01/2016 |
| VECTIVBIO HOLDING AG | Chairman | - |
Formation de Andrew Davis
| Boston University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| IRONWOOD PHARMACEUTICALS, INC. | Health Technology |
| BAUSCH HEALTH COMPANIES INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
BioMarck Pharmaceuticals Ltd.
BioMarck Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology BioMarck Pharmaceuticals Ltd. engages in the discovery and development of new drugs for the treatment of pulmonary diseases and disorders. It develops its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma and cystic fibrosis are later disease targets. The company was founded by Indu Parikh, Allen F. Gant, Thomas H. Roberg and Kenneth Adl in 2002 and is headquartered in Durham, NC. | Health Technology |
Bausch Health US LLC
Bausch Health US LLC Pharmaceuticals: MajorHealth Technology Bausch Health US LLC engages in the development, manufacture and market of pharmaceutical products. It specializes in therapeutic areas of neurology, dermatology, and infectious diseases. The company was founded in 2001 and is headquartered in Raleigh, NC. | Health Technology |
iNova Pharmaceuticals (Pty) Ltd. (South Africa)
iNova Pharmaceuticals (Pty) Ltd. (South Africa) Pharmaceuticals: MajorHealth Technology Part of iNova Pharmaceuticals (Australia) Pty Ltd., iNova Pharmaceuticals (Pty) Ltd. is a South African company that develops and markets a range of healthcare products. The private company is based in Bedfordview, South Africa. The company's products include B-CAL-K2, a calcium and bone health supplement with clinically proven K2, and PregOmega Plus, a multivitamin and mineral supplement for pregnancy. The company is committed to promoting and manufacturing quality products that bring real benefits and comply with Good Manufacturing Practices (GMP). | Health Technology |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Health Technology |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
